皓元医药(688131) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 reached ¥606,125,018.69, representing a 20.05% increase compared to ¥504,874,103.59 in the same period last year[6] - Net profit attributable to shareholders was ¥62,384,400.02, a significant increase of 272.28% from ¥16,757,351.46 year-on-year[6] - The basic earnings per share rose to ¥0.30, reflecting a 275.00% increase compared to ¥0.08 in the previous year[6] - Total operating revenue for Q1 2025 reached ¥606,125,018.69, an increase of 19.99% compared to ¥504,874,103.59 in Q1 2024[24] - Net profit for Q1 2025 was ¥61,178,293.66, a significant increase from ¥16,536,169.84 in Q1 2024, representing a growth of 269.36%[25] - Operating profit for Q1 2025 was ¥74,892,596.81, compared to ¥16,593,800.36 in Q1 2024, marking a growth of 351.36%[25] - The total comprehensive income for Q1 2025 was ¥61,378,679.20, compared to ¥16,883,201.98 in Q1 2024, showing a substantial increase[25] Cash Flow - The net cash flow from operating activities was negative at -¥32,501,676.43, a decline of 214.74% compared to a positive cash flow of ¥28,325,486.01 in the previous year[6] - Cash inflow from operating activities for Q1 2025 was CNY 581,435,370.72, up from CNY 474,799,584.50 in Q1 2024, indicating a growth of 22.4%[26] - The company reported a total cash outflow from operating activities of CNY 613,937,047.15 in Q1 2025, compared to CNY 446,474,098.49 in Q1 2024, which is an increase of 37.5%[26] - Net cash flow from investing activities for Q1 2025 was CNY 63,037,040.70, a significant recovery from negative CNY 119,512,265.14 in Q1 2024[27] - Cash inflow from financing activities for Q1 2025 was CNY 291,805,529.86, compared to CNY 165,645,972.06 in Q1 2024, reflecting a growth of 76.1%[27] - Net cash flow from financing activities for Q1 2025 was CNY 154,932,904.10, up from CNY 59,978,595.17 in Q1 2024, indicating a 158.5% increase[27] Assets and Liabilities - Total assets increased to ¥5,713,528,895.22, up 3.79% from ¥5,504,945,895.27 at the end of the previous year[7] - Total liabilities rose to ¥2,740,169,269.08, compared to ¥2,600,690,964.34 in the previous period, reflecting an increase of 5.36%[22] - Shareholders' equity attributable to shareholders rose to ¥2,948,187,946.51, an increase of 2.44% from ¥2,877,877,144.94 at the end of the previous year[7] - The company's equity attributable to shareholders reached ¥2,948,187,946.51, up from ¥2,877,877,144.94, indicating a growth of 2.45%[22] Research and Development - Research and development expenses totaled ¥53,713,674.32, accounting for 8.86% of revenue, down from 10.62% in the same period last year[7] - Research and development expenses for Q1 2025 were ¥53,713,674.32, slightly up from ¥53,593,858.98 in Q1 2024[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,516[12] - The company approved a stock incentive plan to grant 3,000,000 restricted shares, representing 1.42% of the total share capital, with an initial grant of 2,400,000 shares at a price of RMB 21.62 per share[16][17] Other Financial Metrics - The company reported accounts receivable of RMB 596,903,010.64, an increase from RMB 522,072,402.52, showing a growth of approximately 14.26%[20] - The company’s trading financial assets decreased to RMB 300,150,068.49 from RMB 449,150,068.49, a decline of about 33.24%[20] - The company’s other receivables stood at RMB 28,438,140.36, slightly down from RMB 30,565,123.45, indicating a decrease of approximately 7.00%[20] - The company’s prepayments increased to RMB 16,958,773.48 from RMB 13,183,434.60, reflecting a growth of about 28.00%[20] - The company’s contract assets rose to RMB 43,226,751.19 from RMB 38,101,088.08, marking an increase of approximately 13.00%[20] Governance - The board of directors was restructured, reducing the number of members from 9 to 7, enhancing governance structure and strategic alignment[15] - The company did not apply new accounting standards for the year 2025[28] - The board of directors announced the financial results on April 30, 2025[29]